TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10571597
Drug: Alosetron 1
Normalized name: alosetron 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alosetron 1 mg twice daily
Study: 8387963
Drug: Rufloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rufloxacin (400 mg loading dose on day 1, followed by 200 mg s.i.d.)
Study: 8387963
Drug: Ofloxacin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (300 mg b.i.d.)
Study: 27391321
Drug: Nurse-coordinated prevention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-coordinated prevention programme (NCPP) consisting of four outpatient nurse clinic visits in the first 6 months after the index event, focusing on healthy lifestyles, biometric risk factors, and medication adherence, in addition to usual care.
Study: 15670986
Drug: l-carnitine 990
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-carnitine 990 mg/day + 4 mL/day linseed oil (weeks 5-8)
Study: 15670986
Drug: 4 mL/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mL/day linseed oil (weeks 1-4)
Study: 8181137
Drug: Verapamil (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (0.1 mg/kg)
Study: 10022399
Drug: GnRHa plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRHa plus GH (0.3 mg/kg x week s.c., 6 days weekly, for 2‐4 years)
Study: 8574277
Drug: Dietary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary treatment (5.0 MJ/day diet) for 16 weeks
Study: 31634897
Drug: D-cycloserine (DCS)
Normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D-cycloserine (DCS) 50 mg
Study: 17667888
Drug: D-cycloserine (DCS)
Normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D-cycloserine (DCS) 500 mg
Study: 12814457
Drug: Montelukast 10
Normalized name: montelukast 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 10 mg daily
Study: 3630582
Drug: Midazolam 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.05 mg/kg
Study: 8109230
Drug: Atropine 0.01
Normalized name: atropine 0.0194 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 0.01 mg/kg
Study: 11704448
Drug: Midazolam 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.05 mg/kg + Atropine 0.01 mg/kg
Study: 24991908
Drug: Intervention (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention (24 weekly group sessions led by community care workers)
Study: 18564693
Drug: Albendazole 400
Normalized name: albendazole 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole 400 mg twice daily for 7 days
Study: 11739071
Drug: Animal-assisted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Animal-assisted therapy (AAT) conducted in weekly 4-hour sessions
Study: 8052779
Drug: High-dose mitomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose mitomycin C plus UFT
Study: 8052779
Drug: High-dose mitomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose mitomycin C
Study: 3342553
Drug: Cefazolin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin (1 g before surgery, 500 mg every 8 hours for 6 doses)
Study: 25630840
Drug: Nutritional counselling
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional counselling plus Traditional Chinese Medicine (TCM) acupuncture
Study: 3895539
Drug: Donor-specific transfusions
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donor-specific transfusions (DST) combined with conventional immunosuppressive therapy (azathioprine, prednisone, and antilymphoblast globulin)
Study: 29310631
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g CTE in 400 mL of water
Study: 29310631
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g CTE in 400 mL of water
Study: 12771037
Drug: Oleic acid
Normalized name: Oleic Acid
DrugBank: Oleic Acid (DB04224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oleic acid (OA), 4 g daily for 3 months
Study: 8463443
Drug: Imipramine (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (maximum dose of 300 mg per day)
Study: 4087830
Drug: Oral rifampicin
Normalized name: rifampicin
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral rifampicin (600 mg)
Study: 4087830
Drug: Intravenous rifampicin
Normalized name: rifampicin
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous rifampicin (600 mg)
Study: 23320436
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg gemigliptin qd
Study: 23320436
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg sitagliptin qd
Study: 23320436
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg gemigliptin bid
Study: 23320436
Drug: gemigliptin treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemigliptin treatment
Study: 19145494
Drug: Fesoterodine 8
Normalized name: fesoterodine 8 mg oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fesoterodine 8 mg after high-fat breakfast
Study: 15259543
Drug: Active desensitizing
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active desensitizing agent (UltraEZ) applied daily for 14 days prior to whitening for 30 minutes.
Study: 15259543
Drug: Placebo (same
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (same formulation as UltraEZ without desensitizing agents) applied daily for 14 days prior to whitening for 30 minutes.
Study: 11078068
Drug: Prophylactic perioperative
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic perioperative prednisolone treatment
Study: 29030775
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no prednisolone treatment)
Study: 1555812
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of hydroxyzine (10 mg)
Study: 1555812
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of buspirone (5 mg)
Study: 1555812
Drug: Multi-dose of
Normalized name: VIAL ADAPTER MULTI-DOSE ALARIS #2205E
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-dose of buspirone (5 mg)
Study: 1555812
Drug: Multi-dose of
Normalized name: VIAL ADAPTER MULTI-DOSE ALARIS #2205E
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-dose of chlordiazepoxide (5 mg)
Study: 1555812
Drug: Multi-dose of
Normalized name: VIAL ADAPTER MULTI-DOSE ALARIS #2205E
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-dose of hydroxyzine (10 mg)
Study: 3894589
Drug: Cisplatin 50
Normalized name: cisplatin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 50 mg/m2 every 21 days (regimen 1)
Study: 3894589
Drug: Cisplatin 100
Normalized name: CISPLATIN 100MG/VIL (PF) INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 100 mg/m2 every 21 days (regimen 2)
Study: 23558369
Drug: Fascia iliaca
Normalized name: OCTINOXATE .012 mL in 6 mL / OCTISALATE .12 mL in 6 mL TOPICAL CREAM [RIMMEL LONDON MOISTURE RENEW LIPGLOSS - FUSCIA THERAPHY (345)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fascia iliaca block (30 mL 0.5% ropivacaine)
Study: 19920766
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo (daily for 2 weeks)
Study: 18971523
Drug: Azelnidipine 8
Normalized name: Azelnidipine
DrugBank: Azelnidipine (DB09230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelnidipine 8 mg monotherapy
Study: 18971523
Drug: Temocapril 2
Normalized name: temocapril
DrugBank: Temocapril (DB08836)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temocapril 2 mg monotherapy
Study: 18971523
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (azelnidipine and temocapril)
Study: 12855059
Drug: Successful treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Successful treatments (psychotherapy)
Study: 12855059
Drug: Naturalistic study
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naturalistic study of successful treatments
Study: 8791947
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate 400 mg b.d. plus clarithromycin 500 mg t.d.s. for the first 2 weeks
Study: 8791947
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate 400 mg b.d. for 4 weeks
Study: 1281625
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine and hydromorphone
Study: 31424649
Drug: simple intravenous
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: simple intravenous chemotherapy with cisplatin paclitaxel (TP group)
Study: 31424649
Drug: gene therapy
Normalized name: E1A gene therapy
DrugBank: RGG0853 (DB18669)
Approvals — FDA: no, EMA: no, PMDA: no
Description: gene therapy + intravenous chemotherapy with cisplatin+paclitaxel (rAd‐p53 + TP group)
Study: 26502235
Drug: LEDTB group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEDTB group (photodynamic antimicrobial chemotherapy with light‐emitting diode and toluidine blue solution and RMGIC)
Study: 23839029
Drug: Oral oxycodone
Normalized name: oxycodone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral oxycodone (high dose 45 mg/70 kg)
Study: 23839029
Drug: Oral morphine
Normalized name: morphine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral morphine (high dose 135 mg/70 kg)
Study: 23839029
Drug: Oral morphine
Normalized name: morphine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral morphine (low dose 45 mg/70 kg)
Study: 16253169
Drug: Late course
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late course conformal radiotherapy combined with chemotherapy
Study: 8322572
Drug: Propofol 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2.5 mg.kg‐1
Study: 10215713
Drug: Rocuronium 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.6 mg.kg‐1 with Propofol
Study: 10215713
Drug: Rocuronium 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.6 mg.kg‐1 with Thiopentone
Study: 30666827
Drug: Enalapril 5
Normalized name: enalapril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 5 mg
Study: 389843
Drug: Fluocinonide 0.05%
Normalized name: FLUOCINONIDE 0.05% OINT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluocinonide 0.05% emollient cream
Study: 29770722
Drug: Betamethasone valerate
Normalized name: Betamethasone Valerate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone valerate 0.1% cream
Study: 11260007
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide 0.1% cream
Study: 30302901
Drug: Intralesional triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intralesional triamcinolone acetonide (TRA) injection
Study: 25701560
Drug: 2+1 group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2+1 group (two-dose prime and boost)
Study: 23599118
Drug: Topical anakinra,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anakinra, 2.5% (n = 30)
Study: 23599118
Drug: Topical anakinra,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anakinra, 5% (n = 15)
Study: 20693429
Drug: High-dose daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose daunorubicin
Study: 20693429
Drug: Standard-dose idarubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose idarubicin
Study: 26330288
Drug: Adjunctive placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive placebo
Study: 30509296
Drug: Heparin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin treatment
Study: 15514727
Drug: Refracterin, 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Refracterin, 300 mg/day for 3 days
Study: 18794027
Drug: Aspirin 160
Normalized name: aspirin 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 160 mg
Study: 11524065
Drug: Aspirin 80
Normalized name: aspirin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 80 mg + Warfarin 1 mg
Study: 3546420
Drug: 2% topical
Normalized name: A/T/S 2% Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% topical ketoconazole cream (once or twice daily)
Study: 27738812
Drug: Green/roasted coffee
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green/roasted coffee blend (35/65), 3 servings/day providing 510.6 mg hydroxycinnamic acids and 121.2 mg caffeine/day for 8 weeks
Study: 27257953
Drug: Oxandrolone 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxandrolone 0.1 mg/kg/day in MCT oil
Study: 27257953
Drug: Oxandrolone 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxandrolone 0.2 mg/kg/day aqueous solution
Study: 27257953
Drug: Oxandrolone 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxandrolone 0.1 mg/kg/day aqueous solution
Study: 15850466
Drug: Lamivudine-interferon (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine-interferon (9 MU, t.i.w.) in combination
Study: 27655061
Drug: Diagnostic testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diagnostic testing before antibiotic prescribing
Study: 30865149
Drug: 3 dosing
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 dosing protocols of motor learning-based therapy, identical number of 2-hour sessions over different total calendar weeks
Study: 26673246
Drug: p-synephrine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: p-synephrine (3 mg·kg(‐1))
Study: 2180259
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose bromocriptine
Study: 9196546
Drug: Pyridostigmine bromide
Normalized name: Pyridostigmine Bromide
DrugBank: Pyridostigmine (DB00545)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pyridostigmine bromide (30 mg)
Study: 14739855
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (control group, n=9)
Study: 18041489
Drug: Zolpidem (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem (10 mg)
Study: 2201730
Drug: Triazolam (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam (0.25 mg)
Study: 12680738
Drug: Temazepam (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temazepam (30 mg)
Study: 25873729
Drug: Low-dose unfractionated
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose unfractionated heparin (50 U/kg)
Study: 25873729
Drug: Standard-dose unfractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose unfractionated heparin (85 U/kg or 60 U/kg with glycoprotein IIb/IIIa inhibitors, with ACT guidance)
Study: 25873729
Drug: ACT≤300 s
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT≤300 s (in patients not receiving planned glycoprotein IIb/IIIa inhibitors)
Study: 23703418
Drug: Blind local
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blind local steroid injection
Study: 19482767
Drug: Nebulized 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized 2% lidocaine at 4 mg/kg
Study: 15365964
Drug: 3 mg/kg/dialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg/dialysis iron-sucrose for Group A (iron deficient)
Study: 15365964
Drug: 0.3 mg/kg/dialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg/dialysis iron-sucrose for Group B (iron-replete)
Study: 15365964
Drug: 1 mg/kg/dialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg/dialysis iron-sucrose for Group A (after initial treatment)
Study: 11352248
Drug: Etanercept (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (25 mg subcutaneously twice weekly) added to standard therapies for WG
Study: 15496641
Drug: Etanercept (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (25 mg subcutaneously twice weekly)
Study: 25596138
Drug: BUD/FM BAI
Approvals — FDA: no, EMA: no, PMDA: no
Description: BUD/FM BAI 2 × 160/4.5 μg bid
Study: 21726291
Drug: Antacid tablet
Normalized name: Calcium Carbonate 500 MG Oral Tablet, Chewable [GOOD SENSE ANTACID TABLETS]
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antacid tablet
Study: 21726291
Drug: Gum arabic
Normalized name: Gum arabic
DrugBank: Acacia (DB10451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gum arabic lozenge
Study: 30472992
Drug: Intensive periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive periodontal treatment (IPT)
Study: 16772796
Drug: Bisphosphonate-type compounds
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisphosphonate-type compounds (calcitonin, clodronate, alendronate)
Study: 26372
Drug: Intravenous phentolamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous phentolamine
Study: 7525652
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (HDMTX and LDMTX)
Study: 26333801
Drug: Mindfulness-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based therapy (MT)
Study: 15730346
Drug: Paroxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (20 mg daily)
Study: 10682150
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg zanamivir powder for inhalation
Study: 10682150
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg zanamivir powder for inhalation plus 6.4 mg zanamivir nasal spray
Study: 8922541
Drug: Fasting insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fasting insulin levels of 8.1-12.9 mU/1
Study: 8922541
Drug: Fasting insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fasting insulin levels of 13.0 mU/1 or more
Study: 29332135
Drug: Simultaneous GnRHa
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simultaneous GnRHa treatment
Study: 27521254
Drug: Protein intake
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein intake ≥60 g/d
Study: 21134505
Drug: Letrozole 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole 7.5 mg daily for 2 days followed by 800 mcg vaginal misoprostol
Study: 21134505
Drug: Letrozole 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole 7.5 mg combined with 200 mg mifepristone
Study: 11253444
Drug: NRT use
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRT use among patients offered prescription by a physician
Study: 27987236
Drug: Naltrexone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (100 mg orally)
Study: 3490559
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation during thyroxine therapy
Study: 9599737
Drug: Before treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Before treatment
Study: 29729429
Drug: Clindamycin administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin administered intravenously 30 minutes before incision and every 8 hours for 24 hours post-operation
Study: 29729429
Drug: Sterile saline
Normalized name: Aqua Care Sterile Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile saline administered
Study: 23644179
Drug: Rosuvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (40 mg)
Study: 20202516
Drug: Celecoxib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (200 mg orally twice daily for 5 days) followed by Rosuvastatin (40 mg)
Study: 11212905
Drug: DTIC 750
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTIC 750 mg/m2 IV day 1 every 28 days (Arm A)
Study: 11212905
Drug: DTIC 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTIC 200 mg/m2 IV days 1-5 every 28 days (Arm B)
Study: 2986275
Drug: Alginate/antacid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alginate/antacid
Study: 25547064
Drug: High-dose vancomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vancomycin
Study: 25547064
Drug: Conventional-dose vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional-dose vancomycin
Study: 12631411
Drug: Artemisinin 250
Normalized name: ARTEMISININ
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemisinin 250 (250 mg artemisinin)
Study: 12631411
Drug: beta‐cyclodextrin‐artemisinin complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta‐cyclodextrin‐artemisinin complex (150 mg artemisinin)
Study: 1589726
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment with antibiotics (Control)
Study: 3840029
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g sucralfate
Study: 20594781
Drug: Aged garlic
Normalized name: Garlic 600 MG Oral Tablet [KYOLIC AGED GARLIC EXTRACT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aged garlic extract (960 mg containing 2.4 mg S-allylcysteine) daily for 12 weeks
Study: 9708721
Drug: Amoxicillin and
Normalized name: omeprazole, amoxicillin and rifabutin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin and clavulanate every 12 hours (875 mg amoxicillin; 125 mg clavulanate)
Study: 9708721
Drug: Amoxicillin and
Normalized name: omeprazole, amoxicillin and rifabutin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin and clavulanate every 8 hours (500 mg amoxicillin; 125 mg clavulanate)
Study: 9566550
Drug: VaxSyn (recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: VaxSyn (recombinant HIV envelope subunit vaccine)
Study: 1897329
Drug: 200 IU
Normalized name: Vitamin E 200 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 IU of salmon calcitonin daily as a nasal spray
Study: 23697602
Drug: Lapatinib (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib (1000 mg/day) plus paclitaxel (70 mg/m2 per week, 3 of every 4 weeks) plus trastuzumab
Study: 17353512
Drug: Phenylephrine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine infusion to elevate nocturnal blood pressure to mean daytime values
Study: 8269785
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy combined with daily oral aspirin 100mg